FRIDAY, 15th September
Arch of Constantine Vittoria Bridge
11:00 Bleeding phenotype and target joints predict patients with zero bleeds given once-weekly rophylaxis with BAY94-9027
E. Musi (Switzerland)
Evaluation of a fully–automated chemiluminescent immunoassay for the rapid quantification of ADAMTS13 activity and the detection of ADAMTS13 inhibitors
M. Mirabet (Spain)
11:15 Comparing the one-stage and chromogenic assay: actor VIII activity assay discrepancy at baseline does not eflect assay discrepancy after desmopressin in non-severe hemophilia A patients.
L. Schutte (the Netherlands)
Immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies and its association with HLA-DR-DQ haplotypes and clinical course in acquired thrombotic thrombocytopenic purpura
G. Sinkovits (Hungary)
13:00 BAY 1093884 target the Kunitz Domains 1 and 2 of TFPI and Blocks Its Function
P. Mathew (USA)
Congenital (hereditary) thrombotic thrombocytopenic purpura (cTTP [hTTP], Upshaw–Schulman Syndrome): Patient experience, conceptual framework, and patient-reported outcome (PRO) instrument development
B. Ewenstein (USA)
13:15 Nonacog beta pegol in adult andpaediatric patients: pooled data from the paradigm™ clinical programme
M. Lapecorella (Italy)
Unraveling anti-spacer immunoprofiles of acquired TTP patients using antiidiotypic antibodies
A. S. Schelpe (Belgium)
13:30 Preliminary enrolment data from the U.S. post-marketing safety (PMS) study of rpFVIII in patients with acquired hemophilia
R. Crea (Austria)
Prevention of relapses in patients affected by acquired TTP undergoing elective surgery
B. Ferrari (Italy)
14:00 Nonacog beta pegol for the prophylactic treatment of children with hemophilia B: interim results from the Paradigm™5 clinical trial
M. Lapecorella (Italy)
Possibile repeat time
14:15 Possibile repeat time Possibile repeat time
16:30 Clustered F8 missense mutations cause hemophilia A phenotypic heterogeneity by combination of altered splicing, protein secretion and activity
M. Pinotti (Italy)
Diagnosis of Upshaw-Schulman syndrome in adulthood
B. Ferrari (Italy)
16:45 Von Willebrand factor levels in patients with hemophilia A.
M. Milos (Croatia)
Modeling-guided identification of structural determinants contributing to conformational changes within ADAMTS13
B. Ercig (the Netherlands)
SATURDAY, 16th September
Arch of Constantine Vittoria Bridge
11:00 Whole exome sequencing as a first tier test in diagnosing primary bleeding disorders: WES First
Y. Smit (the Netherlands)
Quantitative ELISA assay for in vivo proteolysis of von Willebrand factor and bleeding: A pilot study in type 2A(IIA) von Willebrand disease
S. Susen (France)
11:15 The rare coagulation factor deficiencies: Single centre experience
F. D. Koseoglu (Turkey)
Development of a gene therapy strategy for von Willebrand disease based on dual adeno-associated virus vectors
E. Barbon (France)
13:00 Possible repeat time Efficacy, safety, and presurgical pharmacokinetics of recombinant VWF (rVWF) in patients with severe VWD who are undergoing elective surgical procedures
F. Peyvandi (Italy)
13:15 Effectiveness and safety of rFVIIa in paediatric Glanzmann Thrombasthenia patients: data from the international Glanzmann Thrombasthenia Registry
A. Roveda (Italy)
Laboratory diagnosis of von Willebrand disease type 2A versus LVAD-induced acquired von Willebrand syndrome
S. Deconinck (Belgium)
13:30 Rare bleeding disorders in the Netherlands
J. Saes (the Netherlands)
Differential diagnosis between type 2A and 2B VWD in a 2-years old female child with a de novo novel mutation
M. T. Pagliari (Italy)
14:00 Simultaneous measurement of thrombin and plasmin generation in patients with Factor XI deficiency
J. Saes (the Netherlands)
Platelet function analyzer measurement of closure time as a biomarker for activity of high and ultralarge multimers of recombinant von Willebrand factor (rVWF)
P. Turecek (Austria)
14:15 Possibile repeat time Possibile repeat time
16:00 Acquired factor V inhibition due to Bactrim therapy – A previously unreported cause of a rare coagulopathy
R. Gately (Australia)
Usefulness of von Willebrand factor propeptide in the differential diagnosis between von Willebrand disease and acquired von Willebrand syndrome
F. Stufano (Italy)
16:15 Hepatitis C viral infection in patients with hemophilia; An experience of Ege Adult Haemophilia Center
F. D. Koseoglu (Turkey)
Recombinant human von Willebrand factor has a unique pattern of ultra large multimers: results from physico, biochemical and in vivo studies
P. Turececk (Austria)
SUNDAY, 17th September
Arch of Constantine Vittoria Bridge
11:00 Development of inhibitors in PUPs:Different scenario, same outcome
S. Trakymiene (Lithuania)
Soluble glycoprotein VI (sGPVI) measurement is a useful biomarker of platelet activation in heparin-induced thrombocytopenia (HIT) and correlates with thrombotic events.
C. W. Tan (Australia)
11:15 A novel macrophage-mediated pathway regulates enhanced clearance of hyposialylated von Willebrand factor in vivo
J. O’Sullivan (Ireland)
Child-onset thrombotic thrombocytopenic purpura: the French Reference Center for Thrombotic MicroAngiopathies experience
B. Joly (France)
13:00 Stabilin-2 deficiency increases procoagulant activity and deep vein thrombosis in mice
A. Michels (Canada)
Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab
R. Gately (Australia)
13:15 Enhanced local disorder in a clinically elusive von Willebrand factor provokes high-affinity platelet clumping
M. Auton (USA)
Possible repeat time
13:30 A cell-based assay to quantify von Willebrand factor mutant binding to integrin αIIbβ3
M. A. Brehm (Germany)
Possible repeat time
14:00 Variability in blood outgrowth endothelial cell characteristics and related von Willebrand factor parameters
A. De Jong (the Netherlands)
Possible repeat time
16:30 Possible repeat time Possible repeat time
16:45 Possible repeat time Possible repeat time